We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal appeals court has affirmed a ruling in favor of Eisai in a patent infringement case over proposed generic versions of its proton pump inhibitor Aciphex, a treatment for gastroesophageal reflux disease.